2demonstrated that combining PIT targeting CD44 with interleukin‐15 (IL‐15), a cytokine that activates natural killer cells, enhances antitumor immunity, leading to stronger tumor growth suppression, prolonged survival, and increased CD8+ T‐cell infiltration compared to monotherapies [333]. This evidence concerns the gene CD44 and neoplasm.